Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
June 26 2023 - 6:10AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2023
Commission File Number 001-38370
CollPlant Biotechnologies Ltd.
(Exact name of registrant as specified in its charter)
4 Oppenheimer St, Weizmann Science Park
Rehovot 7670104, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
This first paragraph of the press release attached
to this Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-229163, 333-248479, 333-263842 and 333-271320)
and Form F-3 (File No. 333-228054, 333-238731 and 333-269087), to be a part thereof from the date on which this report
is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
On June 26, 2023, CollPlant
Biotechnologies Ltd. issued a press release entitled “CollPlant Achieves Milestone and To Receive $10 Million From AbbVie in Accordance
with its Regenerative Dermal Filler Product Collaboration Agreement”. A copy of the letter is attached hereto as Exhibit 99.1 and
is incorporated herein by reference.
Exhibit
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
COLLPLANT BIOTECHNOLOGIES LTD. |
|
|
|
Date: June 26, 2023 |
By: |
/s/ Eran Rotem |
|
|
Name: |
Eran Rotem |
|
|
Title: |
Deputy CEO and
Chief Financial Officer |
CollPlant Biotechnologies (NASDAQ:CLGN)
Historical Stock Chart
From May 2024 to Jun 2024
CollPlant Biotechnologies (NASDAQ:CLGN)
Historical Stock Chart
From Jun 2023 to Jun 2024